Merck is trying to bulk up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.
Source: US Top News and Analysis
Related Posts
Target faces a new boycott over ICE response as retailer presses ahead with turnaround
It is unclear if and how much the AFT boycott could hurt Target, which is…
We’re upgrading our rating on Honeywell — plus 2 positions we’d like to build up
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time…
GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up
For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity…